Extended Release Buprenorphine

DRUG3 trials

Sponsors

Gavin Bart, University of Texas Southwestern Medical Center, Friends Research Institute, Inc.

Conditions

Cocaine Use DisorderOpioid Use DisorderOpioid Use Disorder, ModerateOpioid Use Disorder, SevereSubstance Use Disorder

Phase 2

EXHIT ENTRE Comparative Effectiveness Trial

CompletedNCT04345718

Gavin BartOpioid Use Disorder, Moderate, Opioid Use Disorder, Severe, Substance Use Disorder

Start: 2021-08-09End: 2025-08-27Updated: 2025-12-09

Extended-Release Naltrexone and Monthly Extended-Release Buprenorphine for Cocaine Use Disorder (CURB-2)

CompletedNCT05262270

University of Texas Southwestern Medical CenterCocaine Use Disorder

Start: 2023-04-18End: 2025-07-21Updated: 2025-10-21

Phase 3

Telemedicine XR-B for Individuals in Jail

Active, not recruitingNCT07524738

Friends Research Institute, Inc.Opioid Use Disorder

Start: 2025-06-01End: 2026-09-01Target: 30Updated: 2026-04-24

Related Papers

Randomized, placebo-controlled trial of injectable extended-release naltrexone and injectable extended-release buprenorphine for cocaine use disorder (CURB-2): Study rationale and design.

2025-05-11

Exemplar Hospital Initiation Trial to Enhance Treatment Engagement (EXHIT ENTRE): protocol for CTN-0098 an open-label randomized comparative effectiveness trial of extended-release buprenorphine versus treatment as usual on post-hospital treatment engagement for hospitalized patients with opioid use disorder.

2024-12-02

Promoting alcohol treatment engagement post-hospitalization with brief intervention, medications and CBT4CBT: protocol for a randomized clinical trial in a diverse patient population.

2023-09-195 citations